Novel agents and biomarkers for acute lymphoid leukemia

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Zhao, Yanmin ^a   Huang, He ^a   Wei, Guoqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; Genetic alteration; Monoclonal antibodies; Philadelphia chromosome; Stem cell transplantation; Tyrosine kinase inhibitor

Indexed keywords

ALPHA2A INTERFERON; ASPARAGINASE; BLINATUMOMAB; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; EPRATUZUMAB; IMATINIB; INOTUZUMAB OZOGAMICIN; INTERFERON; METHOTREXATE; NELARABINE; NILOTINIB; REBASTINIB; RITUXIMAB; TRANSCRIPTION FACTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CELL LINEAGE; CLINICAL FEATURE; CYTOGENETICS; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC MARKER; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LONG TERM SURVIVAL; NONHUMAN; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

DISEASE-FREE SURVIVAL; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879041189     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-40     Document Type: Review

References (82)

1. Long-term results of St Jude total therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, et al. Leukemia 2010 24 2 371 382 10.1038/leu.2009.252 20010620
2. Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. Bassan R, Haematologica 2005 90 10 1299 16219555
3. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR, Blood 2008 111 5 2563 2572 10.1182/blood-2007-10-116186 18156492
4. Lack of prognostic significance of monosomal karyotype and absolute lymphocyte count at diagnosis in Philadelphia chromosome negative acute lymphoblastic leukemia. Sirop SJ A-KA, Begna K, Gangat N, Letendre L, Porrata LF, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 1476
5. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, et al. J Hematol Oncol 2013 6 14 10.1186/1756-8722-6-14 23388549
6. The molecular genetic makeup of acute lymphoblastic leukemia. Mullighan CG, Hematology Am Soc Hematol Educ Program 2012 2012 389 396 23233609
7. The Ikaros gene is required for the development of all lymphoid lineages. Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, Sharpe A, Cell 1994 79 1 143 156 10.1016/0092-8674(94)90407-3 7923373 (Pubitemid 24309520)
8. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, et al. N Engl J Med 2009 360 5 470 480 10.1056/NEJMoa0808253 19129520
9. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, et al. Leukemia 2010 24 7 1258 1264 10.1038/leu.2010.87 20445578
10. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, et al. Nature 2008 453 7191 110 114 10.1038/nature06866 18408710 (Pubitemid 351630327)
11. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, et al. J Clin Oncol 2009 27 31 5202 5207 10.1200/JCO.2008.21.6408 19770381
12. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith MA, et al. Blood 2010 115 26 5312 5321 10.1182/blood-2009-09-245944 20139093
13. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Roll JD, Reuther GW, Cancer Res 2010 70 19 7347 7352 10.1158/0008-5472.CAN-10-1528 20807819
14. A BCR-ABL1-like gene expression profile confers a poor prognosis in patients with high-risk acute lymphoblastic leukemia (HR-ALL): a report from Children's Oncology Group (COG) AALL0232. Loh ML HR, Mullighan CG, Linda SB, Devidas M, Borowitz MJ, et al. Blood (ASH Annual Meeting Abstracts) 2011 118 743
15. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, Storlazzi CT, Ottaviani E, Cattina F, Impera L, et al. Clin Cancer Res 2011 17 23 7413 7423 10.1158/1078-0432.CCR-11-1227 22134481
16. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. Hof J, Krentz S, van Schewick C, Korner G, Shalapour S, Rhein P, Karawajew L, Ludwig WD, Seeger K, Henze G, et al. J Clin Oncol 2011 29 23 3185 3193 10.1200/JCO.2011.34.8144 21747090
17. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, et al. Nature 2011 471 7337 235 239 10.1038/nature09727 21390130
18. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Jenkinson S, Koo K, Mansour MR, Goulden N, Vora A, Mitchell C, Wade R, Richards S, Hancock J, Moorman AV, et al. Leukemia 2013 27 1 41 47 10.1038/leu.2012.176 22814294
19. FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. Malyukova A, Brown S, Papa R, O'Brien R, Giles J, Trahair TN, Dalla Pozza L, Sutton R, Liu T, Haber M, et al. Leukemia 2013 27 5 1053 1062 10.1038/leu.2012.361 23228967
20. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, et al. Nat Med 2007 13 10 1203 1210 10.1038/nm1636 17873882 (Pubitemid 47530629)
21. Towards a purely oncogenetic risk classification of adult T-ALL: a GRAALL study. Trinquand A, Tanguy-Schmidt A, Abdelali RB, Lambert J, Lengline E, De Gunzburg N, Payet-Bornet D, Lhermitte L, Mossafa H, Lheritier V, et al. ASH Annual Meeting Abstracts 2012 120 21 881
22. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe JM, Tallman MS, et al. Nat Med 2013 19 3 368 371 10.1038/nm.3078 23377281
23. Adult acute lymphoblastic leukemia: concepts and strategies. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM, Cancer 2010 116 5 1165 1176 10.1002/cncr.24862 20101737
24. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, Del Potro E, Rivas C, Moreno MJ, Tormo M, et al. Haematologica 2010 95 1 87 95 10.3324/haematol.2009.011221 19797728
25. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, et al. J Clin Oncol 2010 28 22 3644 3652 10.1200/JCO.2010.28.1287 20606084
26. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, et al. Blood 2010 116 12 2070 2077 10.1182/blood-2009-12-261586 20466853
27. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, et al. Leukemia 2011 25 1 41 47 10.1038/leu.2010.228 20944676
28. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Ribera JM, Garcia O, Montesinos P, Brunet S, Abella E, Barrios M, Gonzalez-Campos J, Bravo P, Amigo ML, Hernandez-Rivas JM, Br J Haematol 2012 159 1 78 81 10.1111/j.1365-2141.2012. 09240.x 22823211
29. In Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) imatinib (IM) and chemotherapy in combination improve remission rate, stem cell transplantation rate and long-term outcome. Intermesoli TCC, Pogliani EM, Di Bona E, Romani C, Cassibba V, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 662
30. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, et al. J Clin Oncol 2009 27 31 5175 5181 10.1200/JCO.2008.21.2514 19805687
31. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. Thyagu S, Minden MD, Gupta V, Yee KW, Schimmer AD, Schuh AC, Lipton JH, Messner HA, Xu W, Brandwein JM, Br J Haematol 2012 158 4 506 514 10.1111/j.1365-2141.2012.09182.x 22650180
32. Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Ribera JM, Leuk Lymphoma 2013 54 1 21 27 10.3109/10428194.2012. 708753 22762547
33. Dasatinib (sprycel®) and Low intensity chemotherapy for first-line treatment in patients with De novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 study. Rousselot PCM, Huguet F, Lafage M, Leguay T, Salanoubat C, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 666
34. Treating Ph + Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. Papayannidis CFP, Piciocchi A, Di Raimondo F, Pizzolo G, Carella AM, et al. Blood (ASH Annual Meeting Abstracts) 2012 2012 120 2601
35. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, et al. Blood 2007 109 9 3676 3678 10.1182/blood-2006-10- 052746 17213285 (Pubitemid 46641715)
36. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, et al. Blood 2011 118 25 6521 6528 10.1182/blood-2011-05-351403 21931113
37. Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph + ALL). Pfeifer HWS, Binckebanck A, Wassmann B, Käbisch A, Lübbert M, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 1503
38. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY, Han W, Zhang XH, Wang Y, Zhang YY, et al. J Hematol Oncol 2012 5 29 10.1186/1756-8722-5-29 22682059
39. Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation. Farnsworth P, Ward D, Reddy V, Exp Hematol Oncol 2012 1 1 29 10.1186/2162-3619-1-29 23210606
40. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR, Bone Marrow Transplant 2009 43 2 107 113 10.1038/bmt.2008.296 18776928
41. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, Maris MB, Laport GG, Chauncey TR, Lange T, et al. Haematologica 2011 96 8 1113 1120 10.3324/haematol.2011.040261 21508120
42. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Nishiwaki S, Miyamura K, Kato C, Terakura S, Ohashi K, Sakamaki H, Nakao S, Harigae H, Kodera Y, Anticancer Res 2010 30 6 2415 2418 20651401
43. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1 positive acute lymphoblastic leukemia. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, et al. Leukemia 2013 27 6 1254 1262 10.1038/leu.2012.352 23212150
44. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Caocci G, Vacca A, Ledda A, Murgia F, Piras E, Greco M, Arras M, Atzeni S, Littera R, La Nasa G, Biol Blood Marrow Transplant 2012 18 4 652 654 10.1016/j.bbmt.2011.12.587 22240733
45. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Teng CL, Yu JT, Chen HC, Hwang WL, Ann Hematol 2013 [Epub ahead of print]
46. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph + ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Cortes JE KD-W, Pinilla-Ibarz J, le Coutre PD, Chuah C, Nicolini FE, et al. Blood (ASH Annual Meeting Abstracts) 2011 118 109
47. Aurora kinases and their inhibitors: more than one target and one drug. Carpinelli P, Moll J, Adv Exp Med Biol 2008 610 54 73 10.1007/978-0-387-73898-7- 5 18593015
48. A Phase 1 Study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation. Cortes JE TM, Kantarjian HM, Smith H, Bixby D, Rafferty U, et al. Blood (ASH Annual Meeting Abstracts) 2011 118 601
49. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, et al. Blood 2008 111 4 1827 1833 10.1182/blood-2007-10- 116582 18048644 (Pubitemid 351451489)
50. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, et al. J Clin Oncol 2009 27 6 911 918 10.1200/JCO.2008.18.6916 19124805
51. Outcome of pediatric-type therapy for Philadelphia chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA): A Study by the Japan Adult Leukemia Study Group (JALSG ALL202-U study). Sakura THF, Yujiri T, Aoyama Y, Kondo E, Fujimaki K, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 1464
52. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. Ribera JM, Oriol A, Sanz MA, Tormo M, Fernandez-Abellan P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, et al. J Clin Oncol 2008 26 11 1843 1849 10.1200/JCO.2007.13.7265 18398150
53. Peg-asparaginase for acute lymphoblastic leukemia. Rytting M, Expert Opin Biol Ther 2010 10 5 833 839 10.1517/14712591003769808 20345338
54. Pharmacokinetics-Based Modification of Intravenous Pegylated Asparaginase Dosing in the Context of a "Pediatric-inspired" Protocol in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Douer DAI, Lunning MA, Ramezani L, Burke P, Mark L, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 1495
55. L-asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a large compassionate use protocol. Plourde PV JS, Hijiya N, Keller FG, Rheingold SR, Dreyer ZE, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 2568
56. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, et al. Br J Haematol 2011 153 1 58 65 10.1111/j.1365-2141.2011.08588.x 21332712
57. Two Years Follow-up Results of Graspall/Graall-SA2-2008 Study: L-Asparaginase-Loaded Red Blood Cell Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL). Hunault-Berger MLT, Huguet F, Leprêtre S, Deconinck E, Uribe MO, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 1473
58. Targeted drug delivery for cancer therapy: the other side of antibodies. Firer M, Gellerman G, J Hematol Oncol 2012 5 1 70 10.1186/1756-8722-5-70 23140144
59. Novel CD20 monoclonal antibodies for lymphoma therapy. Cang S, Mukhi N, Wang K, Liu D, J Hematol Oncol 2012 5 1 64 10.1186/1756-8722-5-64 23057966
60. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Thomas DA KH, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, et al. Blood (ASH Annual Meeting Abstracts) 2012 2012 120 3572
61. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Hoelzer DHA, Kaul F, Blood (ASH Annual Meeting Abstracts) 2010 116 170
62. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Gupta IV, Jewell RC, Ann N Y Acad Sci 2012 1263 43 56 10.1111/j.1749-6632.2012.06661.x 22830942
63. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Robak T, Curr Opin Investig Drugs 2009 10 6 588 596 19513948
64. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, et al. J Clin Oncol 2008 26 22 3756 3762 10.1200/JCO.2007.15.3528 18669463
65. Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/Cytarabine/Epratuzumab for Relapsed/Refractory Acute Lymphocytic Leukemia. Advani AMS, Coutre S, Wood BL, Radich JP, Mims M, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 2603
66. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, et al. Lancet Oncol 2012 13 4 403 411 10.1016/S1470-2045(11) 70386-2 22357140
67. Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL). O'Brien STD, Jorgensen JL, Kebriaei P, Ravandi F, Kwari M, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 671
68. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Wang K, Wei G, Liu D, Exp Hematol Oncol 2012 1 1 36 10.1186/2162-3619-1-36 23210908
69. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, et al. J Clin Oncol 2011 29 18 2493 2498 10.1200/JCO.2010.32.7270 21576633
70. Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). Topp MS GN, Zugmaier G, Viardot A, Stelljes M, Neumann S, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 670
71. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Furqan M, Mukhi N, Lee B, Liu D, Biomarker Res 2013 1 1 5 10.1186/2050-7771-1-5
72. French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Trioche P, Nelken B, Michel G, Pellier I, Petit A, Bertrand Y, Rohrlich P, Schmitt C, Sirvent N, Boutard P, et al. Exp Hematol Oncol 2012 1 1 39 10.1186/2162-3619-1-39 23227903
73. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Gokbuget N, Basara N, Baurmann H, Beck J, Bruggemann M, Diedrich H, Guldenzoph B, Hartung G, Horst HA, Huttmann A, et al. Blood 2011 118 13 3504 3511 10.1182/blood-2011-01-329441 21715318
74. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). Jain PKH, Thomas DA, Ravandi F, Kadia TM, Burger JA, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 1501
75. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Ram R, Gafter-Gvili A, Vidal L, Paul M, Ben-Bassat I, Shpilberg O, Raanani P, Cancer 2010 116 14 3447 3457 10.1002/cncr.25136 20564092
76. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Kako S, Morita S, Sakamaki H, Ogawa H, Fukuda T, Takahashi S, Kanamori H, Onizuka M, Iwato K, Suzuki R, et al. Leukemia 2011 25 2 259 265 10.1038/leu.2010.260 21072046
77. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, et al. Blood 2010 116 20 4368 4375 10.1182/blood-2010-02-269571 20664060
78. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, et al. Lancet Oncol 2010 11 7 653 660 10.1016/S1470-2045(10) 70127-3 20558104
79. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, et al. Blood 2011 118 2 282 288 10.1182/blood-2011-03-344853 21527516
80. Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. Lv M, Huang X-J, J Hematol Oncol 2012 5 1 10 10.1186/1756-8722-5-10 22424172
81. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Gokbuget N, Hoelzer D, Doubek M, Mayer J, Piatkowska-Jakubas B, Skotnicki AB, Dombret H, et al. Bone Marrow Transplant 2010 45 6 1095 1101 10.1038/bmt.2009.308 19855438
82. MicroRNAs in B cell development and malignancy. Fernando T, Rodriguez-Malave N, Rao D, J Hematol Oncol 2012 5 1 7 10.1186/1756-8722-5-7 22401860